MedPath

A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine

Phase 3
Recruiting
Conditions
Migraine
Registration Number
NCT04396236
Lead Sponsor
Eli Lilly and Company
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

Inclusion Criteria:<br><br> - Participants must have a history of migraine with or without aura as defined by<br> International Headache Society International Classification of Headache Disorders,<br> 3rd edition (ICHD-3) (ICHD-3 2018) diagnostic criteria 1.1 or 1.2.1 and meets the<br> following criteria:<br><br> - History of migraine attacks for more than 6 months<br><br> - Reports at least 2 and no more than 8 moderate-to-severe migraine attacks per<br> month in the 2 months prior to screening visit<br><br> - Duration of a typical untreated migraine attack (excluding sleep) is greater<br> than or equal to 3 hours<br><br> - Participant has not, by history, experienced satisfactory response with a<br> previous migraine therapy, in the opinion of the investigator<br><br> - Participant must be able to swallow a tablet<br><br> - For participants taking migraine preventive medication, treatment regimen is stable<br> and has been taken for at least 3 months prior to screening<br><br> - Participants must weigh at least 15 kilograms (kg)<br><br>Exclusion Criteria:<br><br> - Participants must not be pregnant or nursing<br><br> - Participants must not have any acute, serious, or unstable medical condition<br><br> - Participants must not be actively suicidal or at significant risk for suicide, in<br> the opinion of the investigator

Exclusion Criteria

Not provided

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Percentage of Participants with Pain Freedom (High Dose)
Secondary Outcome Measures
NameTimeMethod
Percentage of Participants with Pain Freedom (Mid Dose);Percentage of Participants with Pain Freedom (Low Dose);Percentage of Participants with Pain Freedom (Age Sub-Groups);Percentage of Participants with Pain Relief;Percentage of Participants Most Bothersome Symptom (MBS)-Free;Percentage of Participants Nausea-Free;Percentage of Participants Photophobia-Free;Percentage of Participants Phonophobia-Free;Percentage of Participants with Sustained Pain Freedom;Percentage of Participants with Sustained Pain Freedom;Percentage of Participants Using Additional Medication for Migraine;Percentage of Participants Using Additional Medication for Migraine;Degree of Migraine Interference in Normal Activities: Percentage of Participants with a Rating of 0 (Not at All), 1 (a Little), 2 (a Lot), or 3 (Completely);Acceptability of the Formulation: Percentage of Participants with a Rating of Very Easy, Easy, Neither Easy nor Hard, Hard, or Very Hard
© Copyright 2025. All Rights Reserved by MedPath